ALK / ROS1 / RET / MET inhibitors

This library includes several ALK, ROS1, RET, and MET inhibitors that have undergone regulatory review for various indications. Augtyro is indicated for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC), demonstrating a Confirmed Overall Response Rate of 79. TEPMETKO is for adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations, with an ORR (%) by Investigator assessment in overall ITT of 54.8. Retevmo is indicated for adult patients with locally advanced or metastatic solid tumors with a RET gene fusion, showing a DCR (Breast) of 100.0. Alecensa is for ALK mutation-positive NSCLC, with a Stratified HR for DFS (alectinib vs chemotherapy, Stage II-IIIA) of 0.24. Zykadia, for ALK-positive NSCLC, reported a Median PFS (ceritinib) of 16 months. Tabrecta, for NSCLC with a MET exon 14 skipping mutation, had a Median OS (months) of 20.76. Rozlytrek is for NTRK fusion positive solid tumours in paediatric patients, with an ORR point estimate in pediatric NTRK+ primary CNS tumours (entrectinib) of 60. Xalkori, for previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), showed an Objective Response Rate (ORR) of 61.2%. Retsevmo, for adults with advanced RET fusion-positive non-small cell lung cancer (NSCLC), had an Objective Response Rate (ORR) of 63.8.

It is important to note that these drugs were studied in different trials, and therefore, the reported figures are not directly comparable head-to-head. Each drug's efficacy and safety profile should be considered within the context of its specific regulatory review and indicated patient population.